Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib
Open Access
- 14 January 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (2), 587-599
- https://doi.org/10.1158/1078-0432.ccr-09-1519
Abstract
Purpose: B-cell receptor signaling plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). However, blocking B-cell receptor signaling with dasatinib, an inhibitor of SRC kinase, produced variable results in preclinical and clinical studies. We aim to define the molecular mechanisms underlying the differential dasatinib sensitivity and to uncover more effective therapeutic targets in CLL. Experimental Design: Fresh CLL B cells were treated with dasatinib, and cell viability was followed. The CLL cases were then divided into good and poor responders. The cellular response was correlated with the activities of B-cell receptor signaling molecules, as well as with molecular and cytogenetic prognostic factors. Results: Among 50 CLL cases, dasatinib treatment reduced cell viability by 2% to 90%, with an average reduction of 47% on day 4 of culture. The drug induced CLL cell death through the intrinsic apoptotic pathway mediated by reactive oxygen species. Unexpectedly, phosphorylation of SRC family kinases was inhibited by dasatinib in good, as well as poor, responders. As opposed to SRC family kinases, activities of two downstream molecules, SYK and phospholipase Cγ2, correlate well with the apoptotic response of CLL cells to dasatinib. Conclusions: Thus, SYK inhibition predicts cellular response to dasatinib. SYK, together with phospholipase Cγ2, may serve as potential biomarkers to predict dasatinib therapeutic response in patients. From the pathogenic perspective, our study suggests the existence of alternative mechanisms or pathways that activate SYK, independent of SRC kinase activities. The study further implicates that SYK might serve as a more effective therapeutic target in CLL treatment. Clin Cancer Res; 16(2); 587–99Keywords
This publication has 40 references indexed in Scilit:
- Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinibLeukemia, 2008
- SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphomaPublished by American Society of Hematology ,2008
- Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlationLeukemia, 2007
- Activation of Peroxisome Proliferator-Activated Receptor γ Contributes to the Survival of T Lymphoma Cells by Affecting Cellular MetabolismThe American Journal of Pathology, 2007
- Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNABlood, 2006
- PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 ActivationLeukemia & Lymphoma, 2004
- The Pathophysiology of Mitochondrial Cell DeathScience, 2004
- ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileBlood, 2003
- Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cellsCell Death & Differentiation, 1999
- The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoireImmunology Today, 1994